Results 11 to 20 of about 13,464,291 (195)

N,N-dimethyltryptamine and Amazonian ayahuasca plant medicine. [PDF]

Hum Psychopharmacol, 2022
AbstractObjectiveReports have indicated possible uses of ayahuasca for the treatment of conditions including depression, addictions, post‐traumatic stress disorder, anxiety and specific psychoneuroendocrine immune system pathologies. The article assesses potential ayahuasca and N,N‐dimethyltryptamine (DMT) integration with contemporary healthcare.
James E, Keppler J, L Robertshaw T, Sessa B.   +3 more
europepmc   +7 more sources

Infoveillance and Critical Analysis of the Systematically Reviewed Literature on Dimethyltryptamine and the “God Molecule”

Pharmaceuticals, 2023
Aboriginals of Latin America have used DMT (N,N-dimethyltryptamine) in ritualistic ceremonies for centuries. Nevertheless, there are limited data on web users’ interest concerning DMT.
Ahmed Al-Imam, Marek A. Motyka, Beata Hoffmann, Anita Magowska, Michal Michalak   +4 more
doaj   +2 more sources

N,N-Dimethyltryptamine

, 2020
A mystery that has been going on for centuries. The N,N-dimethyltryptamine (DMT) molecule, which is found in every living thing, especially in humans at the time of birth and death, and which some claim to open the door of the parallel universes, is a very harmful hallucinogen for some.
YÜCEL, Kamile
core   +3 more sources

Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells. [PDF]

PLoS ONE, 2014
The orphan receptor sigma-1 (sigmar-1) is a transmembrane chaperone protein expressed in both the central nervous system and in immune cells. It has been shown to regulate neuronal differentiation and cell survival, and mediates anti-inflammatory ...
Attila Szabo, Attila Kovacs, Ede Frecska, Eva Rajnavolgyi   +3 more
doaj   +2 more sources

Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials [PDF]

Frontiers in Psychiatry
IntroductionPsychedelic agents have regained the attention of pharmaceutical companies as promising treatments for depressive episodes. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), an atypical psychedelic, is emerging as a potentially effective, novel ...
Aleksander Kwaśny, Alina Wilkowska, Wiesław Jerzy Cubała   +2 more
doaj   +2 more sources

Investigating the Synergistic Neuroprotective Effects of Plant-Derived Antioxidants and the Psychedelic N,N-Dimethyltryptamine in Alzheimer’s Disease Therapy [PDF]

Cells
Alzheimer’s disease (AD) is a chronic and complex neurodegenerative disorder characterized by progressive cognitive decline, memory loss, and irreversible impairment of brain functions.
Júlia Jarne-Ferrer, Mercè Pallàs, Christian Griñán-Ferré, Aina Bellver-Sanchis   +3 more
doaj   +2 more sources

Ayahuasca and Its Main Component N,N-Dimethyltryptamine (DMT) for the Treatment of Mental Disorders: Mechanisms of Action, Clinical Studies, and Tools to Explore the Human Mind [PDF]

Biomedicines
In recent years, psychopharmacology has experienced a significant challenge, highlighting a renewed and strong scientific interest in psychedelics as breakthrough therapies for mental disorders.
Alice Melani, Giorgia Papini, Marco Bonaso, Letizia Biso, Shivakumar Kolachalam, Nicola Luigi Bragazzi, Ciro Conversano, Graziella Orrù, Biancamaria Longoni, Marco Scarselli   +9 more
doaj   +2 more sources

Increased functional connectivity between brain regions involved in social cognition, emotion and affective-value in psychedelic states induced by N,N-Dimethyltryptamine (DMT) [PDF]

Frontiers in Pharmacology
The modulation of social cognition is suggested as a possible mechanism contributing to the potential clinical efficacy of psychedelics in disorders involving socio-emotional and reward processing deficits.
Carla Soares, Carla Soares, Gisela Lima, Gisela Lima, Marta Lapo Pais, Marta Teixeira, Célia Cabral, Célia Cabral, Célia Cabral, Miguel Castelo-Branco, Miguel Castelo-Branco   +10 more
doaj   +2 more sources

Pharmacokinetics of N,N-dimethyltryptamine in Humans. [PDF]

Eur J Drug Metab Pharmacokinet, 2023
N,N-dimethyltryptamine (DMT) is a psychedelic compound under development for the treatment of major depressive disorder (MDD). This study evaluated the preclinical and clinical pharmacokinetics and metabolism of DMT in healthy subjects.The physiochemical properties of DMT were determined using a series of in vitro experiments and its metabolic profile ...
Good M, Joel Z, Benway T, Routledge C, Timmermann C, Erritzoe D, Weaver R, Allen G, Hughes C, Topping H, Bowman A, James E.   +11 more
europepmc   +3 more sources

N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer’s disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk [PDF]

Alzheimer’s Research & Therapy
Background Aberrant neuronal Sigma-1 receptor (Sig-1r)-mediated endoplasmic reticulum (ER)- mitochondria signaling plays a key role in the neuronal cytopathology of Alzheimer’s disease (AD).
Dan Cheng, Zhuo-Gui Lei, Kin Chu, Oi Jin Honey Lam, Chun Yuan Chiang, Zhang-Jin Zhang   +5 more
doaj   +3 more sources